# Quality Assurance Report

---

# Identity

| Field | Value |
|-------|-------|
| QA Report ID | QA-PP-0238 |
| Population Package | PP-0238 |
| Title | Molecular Tumor Profiling |
| Version | 1.0.0 |
| Review Status | PASS |

---

# Layer 1 — Content QA

| Criterion | Result |
|-----------|--------|
| Single educational question | PASS |
| Scope respected | PASS |
| Complete coverage of approved scope | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Knowledge blocks complete | PASS |
| Patient-facing explanations complete | PASS |
| Common misconceptions addressed | PASS |
| Key messages complete | PASS |
| No unnecessary duplication with adjacent PP | PASS |

---

# Layer 2 — Clinical QA

| Criterion | Result |
|-----------|--------|
| Scientifically accurate | PASS |
| Consistent with NCCN Gastric Cancer 2026 | PASS |
| Consistent with ESMO/ASCO Global Curriculum 2023 | PASS |
| Consistent with supporting NCI/ACS material | PASS |
| Molecular profiling correctly distinguished from NGS | PASS |
| Molecular profiling correctly distinguished from somatic genetic testing | PASS |
| Biomarkers used as examples without becoming biomarker-specific packages | PASS |
| Pathology correctly retained as essential clinical context | PASS |
| Actionability presented as context-dependent | PASS |
| Tumor heterogeneity appropriately acknowledged | PASS |
| Molecular evolution appropriately acknowledged | PASS |
| Tissue vs blood/ctDNA boundary preserved | PASS |
| No unsupported universal testing claim | PASS |
| No unsafe medical advice | PASS |

---

# Layer 3 — Educational QA

| Criterion | Result |
|-----------|--------|
| Plain language | PASS |
| Appropriate for patients and caregivers | PASS |
| Technical concepts translated into understandable language | PASS |
| Learning objectives satisfied | PASS |
| NGS explained without excessive technical detail | PASS |
| Molecular profile explained without overwhelming the learner | PASS |
| Common misconceptions corrected | PASS |
| Clinical uncertainty appropriately communicated | PASS |
| Does not imply that every finding is actionable | PASS |
| Does not imply that molecular profiling replaces pathology | PASS |

---

# Layer 4 — Governance QA

| Criterion | Result |
|-----------|--------|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Primary Evidence Package completed | PASS |
| QA Report completed | PASS |
| Evidence traceability complete | PASS |
| Scope boundary maintained | PASS |
| Knowledge Graph complete | PASS |
| Versioning complete | PASS |
| Status metadata complete | PASS |
| Repository-ready structure | PASS |
| Gold artifact naming compliant | PASS |

---

# Clinical Safety Review

| Item | Result |
|------|--------|
| No individualized treatment recommendation | PASS |
| No biomarker-specific treatment algorithm | PASS |
| No claim that NGS is universally required | PASS |
| No claim that molecular profiling replaces pathology | PASS |
| No claim that every molecular alteration is actionable | PASS |
| No individualized interpretation of a genomic finding | PASS |
| No germline-testing instructions | PASS |
| No detailed ctDNA monitoring advice | PASS |
| No unsafe patient instruction | PASS |

---

# Evidence Boundary Review

The package correctly distinguishes three levels:

### Established / guideline-supported

- molecular pathology and genomic testing are components of modern oncology;
- gastric-cancer care incorporates biomarker testing;
- NGS can provide multiple types of molecular information;
- gastric-cancer molecular characterization may include genomic alterations and selected biomarkers;
- molecular findings are interpreted within clinical/pathologic context.

### Context-dependent

- broader genomic profiling;
- the choice of targeted versus broader testing;
- the clinical significance/actionability of an individual finding;
- use of blood-based molecular information.

### Delegated / outside scope

- detailed variant interpretation;
- detailed biomarker testing;
- detailed NGS methodology;
- ctDNA monitoring;
- MRD;
- treatment algorithms.

**Result: PASS**

---

# Educational Boundary Review

The Atomic Knowledge Principle is preserved.

## Included

- molecular tumor profile as an integrated concept;
- types of information that may form the profile;
- relationship to NGS and somatic testing;
- relationship to pathology;
- clinical relevance at a conceptual level;
- limitations.

## Excluded

- individual technology packages;
- detailed biomarker packages;
- variant interpretation;
- germline testing;
- ctDNA-specific methodology;
- treatment decisions.

No material scope creep identified.

---

# Knowledge Graph QA

The package correctly connects:

**PP-0233 Clinical Genomics**

↓

**PP-0235 Somatic Genetic Testing**

↓

**PP-0238 Molecular Tumor Profiling**

↓

**PP-0239 Genomic Biomarkers**

with parallel relationships to:

**PP-0236 Liquid Biopsy**

↓

**PP-0237 ctDNA**

This preserves the approved architecture and prevents duplicate coverage.

---

# Evidence Traceability QA

Primary evidence is traceable to:

1. NCCN Gastric Cancer Version 2.2026 — Principles of Pathologic Review and Biomarker Testing / NGS Biomarker Testing.
2. ESMO/ASCO Global Curriculum 2023 — Molecular Oncology, Molecular Biology/Pathology, Genetic and Genomic Testing, and integrated review of diagnostic materials.
3. NCCN Gastric Cancer Version 2.2025 / JNCCN 2025 — supporting gastric-cancer biomarker framework.
4. American Cancer Society — Stomach Cancer — patient-facing clinical context.
5. NCI — Genetics of Gastric Cancer (PDQ) — supporting genetics boundary.
6. Approved adjacent PP discussions for architecture and scope alignment.

**Result: PASS**

---

# Versioning QA

| Item | Value |
|------|-------|
| Major Version | 1 |
| Minor Version | 0 |
| Patch Version | 0 |
| Release | Gold |
| Release Date | 2026-08-08 |

No major/minor architecture change was introduced after the approved scope lock.

---

# Final Quality Decision

## PASS

**PP-0238 — Molecular Tumor Profiling** satisfies the locked Gold Population Package Specification and the approved PP-0238 Discussion decisions.

The four-artifact package is **Gold Release / Repository Ready**.

---

# Reviewer Notes

PP-0238 is an important **integration node** in the precision-oncology knowledge graph.

Its primary governance value is not to teach another testing technology. Its role is to explain how multiple molecular findings can be integrated into a **molecular description of the tumor**.

The package deliberately maintains the following boundaries:

> **Somatic Genetic Testing = testing process**

> **Molecular Tumor Profiling = integrated tumor molecular characterization**

> **NGS = one technology that can generate molecular information**

> **Variant Interpretation = meaning of detected findings**

> **Genomic Biomarkers = downstream biomarker concept**

> **Liquid Biopsy / ctDNA = complementary blood-based molecular-information pathway**

This architecture minimizes duplication while preserving a coherent patient-facing learning sequence.
